[Experience of the preventive use of the drug Riamilovir in the foci of coronavirus infection (COVID-19)].
Ter Arkh
; 93(4): 435-439, 2021 Apr 15.
Article
in Russian
| MEDLINE | ID: covidwho-1278882
ABSTRACT
AIM:
The assessment of the effectiveness, safety and tolerance of the drug Riamilovir for emergency drug prevention in the foci of a new coronavirus infection (COVID-19). MATERIALS ANDMETHODS:
The trial included 113 persons aged 18 years and older who had level 1 contacts with patients with a new coronavirus infection (COVID-19), who had not previously been ill, with negative PCR results for COVID-19.RESULTS:
The high effectiveness, safety and good tolerance of the preventive use of the drug Riamilovir for the period of 20 days of taking a prophylactic dose of 1 capsule (250 mg) per day in the foci of COVID-19 has been established.CONCLUSION:
The effectiveness and safety of the preventive use of the drug Riamilovir allow to recommend it for emergency drug prophylaxis in contact persons in the foci of a new coronavirus infection (COVID-19).
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Randomized controlled trials
Language:
Russian
Journal:
Ter Arkh
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS